Nano-sized lactic acid bacteria is sterilized lactic acid bacteria with a particle size of less than 1 micron, and disperse when dissolved in water.
From the results of many years of research, it has become clear that regardless of the life and death of lactic acid bacteria its “particle” works on various immune cells in the immune system of the intestine.
So that lactic acid bacteria is expected to work not only for intestinal regulation but also various things such as immunomodulation and aging prevention. In particular, small particle lactic acid bacteria is efficiently absorbed in the intestine, thereby activates immune cells, creates intracellular mediators, and enhances immunity.
Unbalanced immunological system in modern people>
In the small intestine, approximately 60% of the immune cells in the entire body are gathered and the health of one’s body is supported by maintaining a balance between Th1 and Th2 cells, which is the essential components of the immune system.
However, people living in the modern world often tend to disrupt this immunological balance favoring Th2 cells, because of a disturbance of the autonomic nervous system, lifestyle changes, and/or aging.
Nano-sized lactic acid bacteria made by separating adhesion of lactic acid bacteria and dispersing them, can easily pass through Peyer’s patches in the small intestine. This production method can induce Th1 cells and adjust the immunological balance between Th1 and Th2 cells.
Evaluation of IL-12 production inducing activity (in vitro)
When the plant-origin nano-sized lactic acid bacterium SNK and OK432* were compared, the activities were found to be at the same level.
*OK432: Immunotherapeutic agent to increase the immunity of the human body.
(Measurement method)
•Method of measurement for IL-12 production inducing activity
•Using BALB/c mouse: 23 weeks of age
•The concentration of samples at the time of measurement: 10 μg/mL after converting to cell weight

Inhibition of Th17 cell production (Peyer’s patch of mouse ileum)
With the continuous use of the plant-origin nano-sized lactic acid bacterium SNK, the behavior of the immune system cells developing intestinal problems such as colitis was studied.
As a result, a significant dose-dependent inhibition of SNK in the production of Th17 cells, which is relates autoimmune diseases, was observed.
(Test Method)
30 mice were divided into 3 groups of 10 mice (C: only physiological saline solution, L: physiological saline solution + SNK 2mg/kg, H: physiological saline solution + SNK 10mg/kg) and were administered for 15 days. After oral administration for 10 days, dextran sodium sulfate, which induces colitis, was injected to cause inflammation. After dissecting 16 days after administration, analyses for each group were conducted to determine the ratios of Th17 cells and the gene expressions of transcription factor that are related to Th17 cells.

Characteristics of plant-origin Nano-sized lactic acid bacterium SNK®
•Originally found in traditional lactic acid bacteria-fermented food, “Sunki-pickles”.
•A large number of SNK bacteria can be ingested at low dose. (More than 2 trillion lactic acid bacteria/g)
•Superior balance of cytokine production between IL-12 and INF-α.
•Because of the sterilized lactic acid bacteria, they show high stability towards gastric acid and heat and are suitable for a wide range of applications.
•Was patented as a Th1 inducer and its production method (November,2010)
■Product specification etc.
Product name: Plant-origin Nano-particled(Pro)-Biogenics immunophilus SNK
※Plant-origin Nano-sized lactic acid bacterium SNK
Strain name: Lactbacillus plantarum
Country of origin: Japan
Appearance: Pale yellowish-white powder
Solubility: Water-insoluble is disperse in Water
Genetically modified: No used
Storage temperature: Below 20°C
Shipping unit (packaging): 1kg
■Safety studies
•Acute toxicity test
•Residual pesticide test
| Company name |
IHM Inc. |
| Headquarter |
5F,TOC bldg., 7-22-17 Nishigotanda, Shinagawa-Ku, Tokyo 141-0031
Tel +81-3-5435-8657 |
| Capital |
98 million yen |
| Representative |
Shinji Irie, President |
| Business line |
Wholesale of pharmaceuticals, quasi-drugs, health food,
cosmetics, medical devices, etc. Sales of functional food materials,
Health food products planning and development |
| Number of employees |
30 |
| Partner banks |
Hokuriku Bank, MUFG Bank and Kiraboshi Bank |
| Major partners |
KOKANDO Co., Ltd.,
TOKIWA Pharmaceutical Co., Ltd.,
DAITO Pharmaceutical Co., Ltd,
GOSHU YAKUHIN CO., LTD. |
| Group sales company |
Hokkaido Medical Systems Inc.
Yamato Medical Inc.
Shutoken Medical Inc.
Chubu Medical Systems Inc.
Kansai Medical Systems Inc.
Nishinihon Medical Inc.
Kyushu Medical Inc.
Life Medical Inc. |
| Membership of Organization |
The Tokyo Chamber of Commerce and Industry |
Inquiry>